ETON · Eton Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$63.93
+2.48 (+4.04%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.84B
Shares
28.84M
Volume · Nov 13
601.31K
Avg daily vol (3M)
618.9K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Eton Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Eton Pharmaceuticals, Inc. (ETON), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript
Confident tone
ET700 formulation optimization
ET900 infantile spasms program
ASN-001 pipeline opportunity
Revenue
$57.92M
▲ 157.9% YoY Diluted EPS
$1.06
Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-13
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Confident tone
Pediatric dermatology franchise and ASN-001
Pipeline and label expansion
Margin expansion and profitability
Revenue
$37.59M
▲ 98.6% YoY Diluted EPS
$0.35
Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Eton Pharmaceuticals, Inc. (ETON) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Confident tone
Product launches
Rare disease portfolio diversification
Hemangiol acquisition and patient transition
Revenue
$24.27M
▲ 40.4% YoY Diluted EPS
$0.05
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Confident tone
Financial results and growth
Desmota launch
Clinical development pipeline
Revenue
$21.28M*
▲ 82.7% YoY Gross margin
61.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
Confident tone
KHINDIVI launch and reformulation
Label expansion and clinical pipeline
Pricing and gross margin outlook
Revenue
$22.46M
▲ 117.5% YoY Diluted EPS
$-0.07
▼ 450% YoY Gross margin
35.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
Confident tone
Increlex acquisition performance and patient growth
Khindivi FDA approval and launch
ET-600 NDA submission and PDUFA
Revenue
$18.93M
▲ 108.6% YoY Diluted EPS
$-0.10
Gross margin
63.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
Confident tone
ET-400 (liquid hydrocortisone) approval and launch
Increlex relaunch and patient growth
Galzin and Wilson disease franchise
Revenue
$17.28M
▲ 116.9% YoY Diluted EPS
$-0.06
Gross margin
57.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Eton Pharmaceuticals, Inc. (ETON) Q4 2024 Earnings Call Transcript
Confident tone
2025 Financial Outlook and Ramp Expectations
Acrolex / Galzum Acquisition
Adrenal Insufficiency Franchise (Alkindi/ET400)
Revenue
$11.65M*
▲ 59.3% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Confident tone
Pipeline and ET-400
Increlex Acquisition
Metabolic Portfolio
Revenue
$10.32M
▲ 46.9% YoY Diluted EPS
$0.02
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Confident tone
Product sales growth and streak
ET-400 pipeline and NDA
Carglumic Acid and metabolic portfolio
Revenue
$9.07M
▼ 24.4% YoY Diluted EPS
$-0.12
▼ 166.7% YoY Gross margin
62.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Eton Pharmaceuticals, Inc. (ETON) Q1 2024 Earnings Call Transcript
Confident tone
ET-400 NDA submission and launch
ALKINDI SPRINKLE performance and discontinuation
PKU GOLIKE acquisition
Revenue
$7.97M
▲ 50.2% YoY Diluted EPS
$-0.03
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Confident tone
Revenue growth and commercial momentum
ET-400 pipeline and liquid hydrocortisone
Business development and acquisitions
Revenue
$7.31M*
▼ 13.9% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Eton Pharmaceuticals, Inc. (ETON) Q3 2023 Earnings Call Transcript
Revenue
$7.03M
▲ 118.3% YoY Diluted EPS
$-0.02
Gross margin
62.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Eton Pharmaceuticals, Inc. (ETON) Q2 2023 Earnings Call Transcript
Revenue
$12.00M
▲ 63% YoY Diluted EPS
$0.18
Gross margin
80.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Eton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call Transcript
Revenue
$5.30M
▲ 143.8% YoY Diluted EPS
$-0.10
Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Call Transcript
Revenue
$8.50M*
▲ 39.5% YoY Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Eton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Call Transcript
Revenue
$3.22M
▲ 315.4% YoY Diluted EPS
$-0.12
Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Eton Pharmaceuticals, Inc. (ETON) Q2 2022 Earnings Call Transcript
Revenue
$7.36M
▲ 139.9% YoY Diluted EPS
$-0.06
Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Eton Pharmaceuticals, Inc. (ETON) Q1 2022 Earnings Call Transcript
Revenue
$2.18M
▼ 81.7% YoY Diluted EPS
$-0.21
▼ 210.5% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2021 Earnings Call Transcript
Revenue
$6.09M*
▲ 7422.2% YoY Gross margin
93.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Eton Pharmaceuticals, Inc. (ETON) Q3 2021 Earnings Call Transcript
Revenue
$775,000
Diluted EPS
$-0.24
Gross margin
15.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Eton Pharmaceuticals, Inc. (ETON) Q2 2021 Earnings Call Transcript
Revenue
$3.07M
▲ 15235% YoY Diluted EPS
$-0.08
Gross margin
94.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Eton Pharmaceuticals, Inc. (ETON) Q1 2021 Earnings Call Transcript
Revenue
$11.90M
▲ 11917.2% YoY Diluted EPS
$0.19
Gross margin
86.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2020 Earnings Call Transcript
Revenue
$81,000*
▼ 82.4% YoY Gross margin
-455.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Eton Pharmaceuticals, Inc. (ETON) Q3 2020 Earnings Call Transcript
Revenue
−$161,000
Gross margin
10.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Eton Pharmaceuticals, Inc. (ETON) Q2 2020 Earnings Call Transcript
Revenue
$20,000
Diluted EPS
$-0.23
Gross margin
-40.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Eton Pharmaceuticals, Inc. (ETON) Q1 2020 Earnings Call Transcript
Revenue
$99,000
▼ 80.2% YoY Diluted EPS
$-0.50
Gross margin
-3.0%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-06
Eton Pharmaceuticals, Inc. (ETON) Q4 2019 Earnings Call
Revenue
$459,000
Rev · 2q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1710340
CUSIP
29772L108
13F (30d)
154 filings
151 filers
Visit website
Investor relations